Search Bar & Filters
Found 6 Actively Recruiting clinical trials
Actively Recruiting
The trial investigates the effectiveness and safety of two dosing schedules of pegozafermin compared to a placebo in adults with metabolic dysfunction-associated steatohepatitis MASH who have liver fibrosis stages F2 or F3. This phase 3 study focuses on people aged 18 to 80 years and aims to better understand treatment options for this liver condition. Participants will be randomly assigned to receive one of two pegozafermin regimens or a matching placebo. Both pegozafermin and placebo are given by subcutaneous injection. The study includes a treatment period lasting up to 52 weeks, during which the effects of these regimens on liver fibrosis and steatohepatitis will be assessed. Throughout the study, participants will undergo various evaluations including liver biopsies, blood tests measuring liver enzymes and fibrosis markers, and monitoring for disease progression for up to five years. Researchers will track improvements in liver fibrosis, resolution of steatohepatitis, changes in liver enzyme levels, and fibrosis scores to assess the impact of the treatments.
Actively Recruiting
Researchers are evaluating the efficacy and safety of pegozafermin in adults aged 18 to 75 years who have biopsy-confirmed and clinically confirmed compensated cirrhosis caused by metabolic dysfunction-associated steatohepatitis MASH. This phase 3 study aims to compare pegozafermin against a matched placebo to better understand its effects on liver fibrosis and disease progression in this population. Participants will receive either pegozafermin or a placebo through subcutaneous injections. The study is randomized and quadruple-blinded, ensuring neither participants nor researchers know which treatment is given. Treatment effects will be observed over a period of up to 5 years, with primary outcomes measured at 24 months, including fibrosis regression and time to disease progression based on specified clinical events. Throughout the study, participants will undergo regular assessments, including liver function tests like ALT and AST, enhanced liver fibrosis scores, FibroScan elastography, and evaluations for portal hypertension and other liver-related complications. Safety monitoring will track adverse events during the treatment and follow-up period. The trial spans several years, allowing long-term observation of treatment outcomes and participant health.
Actively Recruiting
Researchers are evaluating the pharmacokinetics, pharmacodynamics, efficacy, and safety of anifrolumab infusion compared with placebo in children aged 5 to under 18 years with moderate to severe active systemic lupus erythematosus SLE who are on standard background therapy. This phase III study aims to better understand how anifrolumab works and its effects in pediatric SLE patients. Participants are randomly assigned to receive either anifrolumab or a matching placebo via intravenous infusion every 4 weeks. The study includes multiple periods a screening period up to 30 days Part A, a four-week double-blind, placebo-controlled pharmacokinetic phase Part B, a double-blind, placebo-controlled safety and efficacy phase lasting 48 to 52 weeks depending on prior participation Part C, a 52-week open-label extension and Part D, a safety follow-up with one visit 12 weeks after the last dose. During the study, participants undergo various assessments including blood tests to measure drug levels, immune markers, and disease activity using specific lupus assessment tools. Researchers monitor response to treatment, safety, and changes in corticosteroid use over time. The total participation lasts about 116 weeks, with scheduled visits for infusions and evaluations to track disease progress and treatment effects.
Actively Recruiting
Researchers are studying the impact of the Accu-Chek SmartGuide continuous glucose monitoring CGM device in adults with Type 1 or insulin-dependent Type 2 diabetes who use multiple daily insulin injections. The trial compares the time their blood glucose levels stay within the target range of 70 to 180 mgdL when using the CGM device versus traditional self-monitoring of blood glucose SMBG. This open-label, randomized study aims to gather data on glucose management improvements with the new device. Participants are assigned to one of two groups one group uses the Accu-Chek SmartGuide CGM solution, which includes a sensor, a device, and smartphone apps that provide real-time glucose readings and data analysis. The control group continues using SMBG with a blinded CGM sensor during assessment periods, meaning they cannot see real-time glucose data. The study includes baseline and multiple assessment periods over 26 weeks to measure changes in glucose control markers. During the study, participants will have their blood glucose levels monitored and compared across different periods using the CGM or SMBG methods. Researchers will collect data on time spent within glucose target ranges, hypoglycemia and hyperglycemia events, average glucose levels, insulin doses, carbohydrate intake, and questionnaire scores related to diabetes distress and fear of hypoglycemia. The study lasts approximately 27 weeks, including baseline and three assessment periods, with multiple visits and data collection to understand the devices impact on glucose management.
Actively Recruiting
Researchers are conducting an observational study to screen adults aged 18 and over who visit hospital outpatient clinics in Turkey for malnutrition and sarcopenia risks. The study focuses on patients attending oncology, neurology, and geriatric clinics to better understand these conditions across diverse patient groups. This non-interventional, cross-sectional design means participants are observed without receiving experimental treatments. Participants are screened once during their outpatient visit without any study treatments or interventions. The study collects information on malnutrition risk, sarcopenia risk, body mass index, calf circumference, hand grip strength, biochemical parameters, healthcare use, and nutrition treatments. Data is gathered on the screening day only. During the study visit, researchers will assess physical and biochemical measures to evaluate nutrition and muscle health. Participants provide informed consent before any assessments. The study measures malnutrition and sarcopenia risks as primary outcomes on the first day and includes several secondary measures related to body composition and healthcare use. The study will continue enrolling participants until April 2027.
Actively Recruiting
This research aims to provide continued access to the drug anifrolumab for participants who have completed a previous clinical study and are assessed by the Investigator to still benefit from ongoing treatment. The study focuses on monitoring the long-term safety and tolerability of anifrolumab in people with conditions including Systemic Sclerosis, Cutaneous Lupus, Myopathies, and Systemic Lupus Erythematosus. Participants must have received at least one dose of anifrolumab in the prior study and be considered suitable to continue treatment. Participants will receive anifrolumab in the same form and manner as in the parent trial, which may be via pre-filled syringe, pre-filled pen, or infusion. This is an open-label study without randomization, where all participants continue on anifrolumab until they meet study discontinuation criteria. Those with treatment gaps or on compassionate use can also enroll. The study enrollment visit occurs at the end of the parent study after all safety follow-up assessments are complete. Throughout the study, safety monitoring includes collecting data on serious and non-serious adverse events from the first dose until 12 weeks after the last dose of anifrolumab. Participants will be followed until they discontinue, with ongoing assessments of tolerability. The study duration extends until December 2032, allowing long-term observation of treatment effects and safety.